Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA

Learn more about:
Related Clinical Trial
Clinical Profile of Neonates Having Patent Ductus Arteriosus Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen Aminoglycosides and Duct Radiation-Free Heart Catheterization Using MRI Hemodynamic Responses to Cardio-respiratory Events in Preterm Infants Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease The Preterm Infants’ Paracetamol Study Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Evaluation of the Brain and Renal Regional Oxygenation Using NIRS in Preterm Infants Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD Hyperion™ International Registry Trial NIRS in PDA VLBW Infants Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants Lifetech CeraFlex™ Post-Market Surveillance Study Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications Nit-Occlud PDA Post-Approval Study Ibuprofen and Renal Function in Premature Infants A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation Canadian National PDA Treatment Study Long Term Results of 450 Percutaneous Closures of PDA in a Single Center Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants AMPLATZER Duct Occluder II Additional Sizes A NEW SCORING SYSTEM FOR PREDICTION OF PDA Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants The Efficacy of Implementing a Treatment Algorithm in Managing Patent Ductus Arteriosus (PDA) in the Extremely Low Birth Weight Neonatal Population. Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA) Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Addition of Acetaminophen in Standard PDA Management Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Paracetamol Versus Ibuprofen for PDA Closure Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants Early Treatment Versus Expectative Management of PDA in Preterm Infants International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Do Elevated BNP Levels Predict Hemodynamically Significant PDAs The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants Brain, Gut and Kidney Blood Flow During Medical Closure of PDA Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term AMPLATZER Duct Occluder II Clinical Study The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth Paracetamol and Patent Ductus Arteriosus (PDA) Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure Pocket Echocardiography System (PES) for Detection of PDA in Neonates Treating the Resistant Patent Ductus Arteriosus (PDA) Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus IV Acetaminophen and Patent Ductus Arteriosus Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus. Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus

Brief Title

Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA

Official Title

Comparison of Intravenous Ibuprofen vs. Continuous Indomethacin in the Treatment of Patent Ductus Arteriosus

Brief Summary

      The purpose of this study is to determine whether closure of the PDA in premature neonates
      using IV ibuprofen vs continuous IV indomethacin has different side effects, eg. effects on
      renal function, on blood flow velocity in the superior mesenteric artery, the anterior
      cerebral artery, and the renal artery.

Detailed Description

      Despite the fact that ibuprofen appears to minimize the renal side effects seen following
      bolus indomethacin, other concerns regarding both short and long-term safety remain.
      Indomethacin, on the other hand, has been used to treat premature neonates for many years.
      Other than transient vasoconstrictive effects, no significant toxicity has been noted. Thus,
      if we were to be able to eliminate the differential renal effects, indomethacin would remain,
      for many, the therapy of choice for the premature neonate with a persistent PDA. We
      hypothesized that continuous administration of indomethacin would provide this option.
      Ibuprofen therapy has not, to date, been compared with indomethacin administered by
      continuous infusion. Hence, in the current study we attempted to determine whether continuous
      indomethacin administration could potentially offer the same advantages as ibuprofen in
      treating PDA, specifically in terms of mitigation of renal side effects. Specifically, our
      primary objective was to show no differences in urine output and/or in serum creatinine
      between the treatment groups. As a secondary objective, we aimed to show no other potentially
      vascular-mediated clinical differences, eg. Necrotizing enterocolitis (NEC), intraventricular
      hemorrhage (IVH), retinopathy of prematurity (ROP) and on bilirubin albumin binding between
      the groups.

      B-type natriuretic peptide (BNP) is released by ventricular myocytes in response to
      ventricular volume load. It, in turn, mediates vasodilation, natriuresis and diuresis. Serum
      BNP levels have been shown to be clinically useful in differentiating between respiratory and
      cardiac disease, in monitoring heart failure therapies and in serving as early diagnostic
      biomarkers of ductal patency in premature neonates. As secondary objectives we intend to
      determine whether a decrease in BNP levels would be an equally reliable indicator of
      therapeutic efficacy in infants treated with ibuprofen as with indomethacin.In addition we
      will look at comparative effects on other vascular beds which might mediate long term side
      effects described above.

Study Phase

Phase 3

Study Type


Primary Outcome

To show no differences in urine output and/or in serum creatinine between the treatment groups

Secondary Outcome

 To show no other clinical differences, eg. NEC, IVH or ROP between the groups; to study doppler flow velocities to these areas; to correlate with BNP levels.


Patent Ductus Arteriosus


Continuous indomethacin


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 2002

Completion Date

September 2006

Eligibility Criteria

        Inclusion Criteria:

          -  < 1500 gm birth weight with PDA confirmed by echocardiography

        Exclusion Criteria:

          -  Additional congenital heart lesions

          -  Significant congenital malformations

          -  Documented infection

          -  Thrombocytopenia (<60,000)

          -  IVH grade 4




N/A - 3 Weeks

Accepts Healthy Volunteers



Cathy Hammerman, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Study Sponsor

Shaare Zedek Medical Center

Study Sponsor

Cathy Hammerman, MD, Principal Investigator, Shaare Zedek Medical Center

Verification Date

June 2007